References
- Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4(12):2186–2207.
- Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–2554.
- Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738.
- Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563–1573.
- Patel KK, Giri S, Parker TL, et al. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. J Clin Oncol. 2021;39(10):1119–1128.
- Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
- Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107.
- Dimopoulos MA, Delimpasi S, Simonova M, et al. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J Clin Oncol. 2020;38(15 Suppl.):8501.
- Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157.
- Arias E, Xu J, Kochanek KD. United States Life Tables, 2016. Natl Vital Stat Rep. 2019;68(7):1–66.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32(2):101–108.
- Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.
- Barnes JI, Divi V, Begaye A, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2(15):1946–1956.
- Fiala MA, Gettinger T, Wallace CL, et al. Cost differential associated with hospice use among older patients with multiple myeloma. J Geriatr Oncol. 2020;11(1):88–92.
- Center for Medicare and Medicaid Services. 2020 ASP drug pricing files; 2020; [cited 2020 Dec 21]. Available from: https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/2020-asp-drug-pricing-files
- Lien K, Cheung MC, Chan KK. Adjusting for drug wastage in economic evaluations of new therapies for hematologic malignancies: a systematic review. J Oncol Pract. 2016;12(4):e369–e379.
- Center for Medicare and Medicaid Services. 2020 physician fee schedule; 2020; [cited 2020 Mar 21]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx
- Center for Medicare and Medicaid Services. Medicare plan finder; 2020; [cited 2020 Apr 14]. Available from: https://www.medicare.gov/find-a-plan/questions/home.aspx
- Memorial Sloan Kettering. DrugPricingLab; 2020; [cited 2020 Aug 4]. Available from: https://drugpricinglab.org/tools/drug-abacus/methods/
- Patel KK, Isufi I, Kothari S, et al. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136(17):1946–1955.
- Center for Medicare and Medicaid Services. 2020 Q4 clinical laboratory fee schedule; 2020; [cited 2020 Dec 20]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files
- Center for Medicare and Medicaid Services. FY 2020 OPPS final rules; 2020; [cited 2020 Jan 24]. Available from: https://www.cms.gov/index.php/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index
- US Bureau of Economic Analysis. Price indexes for personal consumption expenditures by function; 2020; [cited 2020 Aug 4]. Available from: https://apps.bea.gov/iTable/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=survey
- Hatswell AJ, Burns D, Baio G, et al. Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data. Health Econ. 2019;28(5):653–665.
- Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.
- Bassali J, Gould IG, Kaye JA, et al. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020;12:317–325.